Morphine
Drugoral morphine (0.5 mg / kg)
NCT Number: NCT06464146
The purpose of this study is to determine if IN fentanyl (1.5 µg/kg) or IN ketamine (1 mg/kg) is more effective at 30 minutes than oral morphine (0.5 mg/kg) in reduction of moderate and severe pain associated with limb injuries in patients 2-17 years of age presenting to the ED.
Interested in participating?
Request Info2 year–17 year
All sexes
Interventional
Phase 3
Ambroise Paré Hospital, Boulogne-Billancourt, France
In children with moderate to severe pain due to musculoskeletal injuries, the first-line analgesic therapy in pediatric emergency departments (ED) is oral or intravenous morphine. Due to the delay or discomfort associated with establishing IV access, oral forms are preferred in French ED. Unfortunately, oral morphine alone or with ibuprofen or paracetamol, none regimen is optimal for relieving pain in children with traumatic limb injuries. However, the use of intranasal course is a safe route that can provide rapid and almost immediate analgesia. Intranasal administration is easy, non-invasive and usually well tolerated by children. In the last years, drugs with analgesic and sedative properties is increasing, particularly on fentanyl, ketamine, which can be also administered by the IN route. There are currently no studies, neither published nor ongoing, which compare IN fentanyl or IN ketamine to a standard oral morphine for children with acute moderate to severe pain with limb injuries presenting to the ED. The main hypothesis is that the efficacy of the analgesia 30 minutes after the administration will be higher with IN Fentanyl or with IN Ketamine, when compared to oral morphine.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral morphine (0.5 mg / kg)
IN fentanyl (1.5 µg/kg)
IN ketamine (1 mg/kg)
Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
Time frame: 30 minutes
Success: children <7 years with a pain score assessed by Evendol < 5 years, 30 minutes after drugs administration, without rescue analgesia. Scale: 0-15 (no pain - painful)
Time frame: 30 minutes
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 30 minutes after drugs administration, without rescue analgesia. Visual Analog Scale : 0-100 (no pain- painful)
Time frame: 15 minutes
Success: children <7 years with a pain score assessed by Evendol < 5, 15 minutes after drugs administration, without rescue analgesia
Time frame: 15 minutes
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 15 minutes after drugs administration, without rescue analgesia
Time frame: 60 minutes
Success: children <7 years with a pain score assessed by Evendol < 5, 60 minutes after drugs administration, without rescue analgesia
Time frame: 60 minutes
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 60 minutes after drugs administration, without rescue analgesia
Time frame: 90 minutes
Success: children <7 years with a pain score assessed by Evendol < 5, 90 minutes after drugs administration, without rescue analgesia
Time frame: 90 minutes
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 90 minutes after drugs administration, without rescue analgesia
Time frame: 120 minutes
Success: children <7 years with a pain score assessed by Evendol < 5, 120 minutes after drugs administration, without rescue analgesia
Time frame: 120 minutes
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 120 minutes after drugs administration, without rescue analgesia
Time frame: 15 minutes
Reduction in pain from baseline assessed by Evendol for children <7 years
Time frame: 15 minutes
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
Time frame: 30 minutes
Reduction in pain from baseline assessed by Evendol for children <7 years
Time frame: 30 minutes
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
Time frame: 60 minutes
Reduction in pain from baseline assessed by Evendol for children <7 years
Time frame: 60 minutes
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
Time frame: 90 minutes
Reduction in pain from baseline (assessed by VAS for children ≥ 7 years)
Time frame: 90 minutes
Reduction in pain from baseline assessed by Evendol for children <7 years
Time frame: 120 minutes
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
Time frame: 120 minutes
Reduction in pain from baseline assessed by EVENDOL for children < 7 years
Time frame: 30 minutes
Success pain evaluation, as defined in primary outcome (for the comparison between ketamine and fentanyl) assessed by Evendol for children <7 years
Time frame: 30 minutes
Success pain evaluation, as defined in primary outcome (for the comparison between ketamine and fentanyl) assessed by VAS for children ≥ 7 years
Time frame: 5 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 10 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 15 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 30 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 60 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 90 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: 120 minutes
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
Time frame: From study treatment intake until ED discharge, up to 1 day
Adverse events potentially associated with IN ketamine, IN fentanyl and/or oral morphine: drowsiness, dizziness, pruritus, nausea, vomiting, dysphoria, nasal burning and irritation, unpleasant taste, vision changes, throat irritation, headache, vital sign changes (heart rate, respiratory rate, oxygen saturation, blood pressure).
Time frame: At ED discharge, up to 1 day
General satisfaction of parents and patient ≥ 7 years old on a scale of 0-100 with corresponding faces (0 = no satisfaction at all, 100 = very satisfied)
Contact information is provided by the study sponsor or research team.
Hélène CHAPPUY, MD, PhD
CONTACT
Nelly BRIAND, PhD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Pain Reduction for Limb Injuries in Pediatric Emergency Departments: A Randomised Clinical Trial Comparing Intranasal Fentanyl or Intranasal Ketamine to Oral Morphine
Acronym: ANTAMIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06902636
Barthel Index, Geriatric
Kaohsiung City, Kaohsiung, Taiwan
View Trial DetailsNCT07066371
Anxiety, Anxiety Disorders
Bitlis, Turkey (Türkiye)
View Trial DetailsNCT05669157
Disease Attributes, Emergencies
Orléans, France
View Trial DetailsNCT03446131
Limb Injury
San Diego, California, United States
View Trial Details